Test your knowledge of the diabetes technology prior authorization process with 11 practical scenarios. Choose the best next step and review explanations to reinforce your understanding. About 6 minutes.
Developed by danatech clinical staff and reviewed by the ADCES Diabetes Technology Committee. Last reviewed October 2026
About this knowledge check: These scenarios support learning, not certification. A score does not demonstrate competence in managing actual requests. Payer processes vary by plan.
What it covers
Preparing a requestResponding to a denialEscalatingUsing AIAfter approvalPractice setup
Scenarios follow a request from first check to renewal.
How are you taking it?
Taking it only once? Choose After reading the guide.
The interactive version needs JavaScript. All eleven scenarios are listed below, with the answer key at the end.
Scenario 1 of 11
Scenario map
1. Preparing a request
2. Preparing a request
3. Preparing a request
4. Responding to a denial
5. Responding to a denial
6. Escalating
7. Escalating
8. Using AI
9. After approval
10. Practice setup
11. Practice setup
Best stepRevisitAnswered
Answer key and explanations
Scenario 1: B. A prior approval does not establish coverage under a new plan. Benefit verification identifies whether the request belongs under the pharmacy or medical/durable medical equipment benefit, whether prior authorization (PA) is required and which current policy and submission process apply. The other choices act on requirements that may no longer apply.
Scenario 2: D. A general checklist is a prompt to check requirements, not a universal coverage rule. Do not add testing or a prior pump trial solely because it appears on the checklist. Complete applicable documentation and clinical checks, including the requested system’s indicated use, component compatibility and training support. No exception is needed for a criterion the plan does not require.
Scenario 3: A. The checklist includes documentation of the clinical rationale for the requested smart insulin pen. A current insulin regimen, A1C and smartphone compatibility do not independently establish why the technology is being requested for this person. The care team should obtain an individualized rationale based on documented clinical circumstances and verify the payer's requirements. Do not invent dosing history or promise clinical outcomes that have not been established.
Scenario 4: C. The stated barrier is an administrative gap. Supply the required signature through the plan’s applicable process and retain proof of submission. More clinical evidence does not fix an unsigned order. Similarly, a coding-related denial calls for checking the code against the documented diagnosis, rather than choosing a code solely to obtain approval.
Scenario 5: B. The person genuinely does not meet the stated criterion. More documentation cannot establish medication use that is absent. An available exception or appeal should acknowledge the unmet criterion and explain the documented clinical rationale. Clinical appropriateness and payer eligibility are distinct. Do not alter coding or treatment solely to make the request appear eligible.
Scenario 6: A. Expedited review depends on applicable urgency requirements and the documented clinical circumstances. An urgent label, cost burden or medication titration alone does not automatically establish eligibility. The case study’s accepted expedited request and decision timeline describe that case; they are not a universal rule for every plan or appeal.
Scenario 7: C. A peer-to-peer request does not, by itself, establish that an appeal was filed or that its deadline was extended. Confirm the plan’s procedures, preserve the formal appeal opportunity and retain submission confirmation. The discussion may still help clarify the clinical rationale within the applicable process.
Scenario 8: C. Follow organizational privacy, security and AI policies, including approval for the tool and the proposed use of patient information. Removing a name alone does not establish de-identification. Provide verified facts and criteria, tell the tool to flag gaps and independently check clinical statements, dates, coverage claims and citations. Tool approval does not remove the need to verify its output.
Scenario 9: D. Approval is an important milestone, but it does not establish that the person received the device or supplies. Obtain the written determination, confirm covered components, dates and the correct pharmacy or supplier, and resolve the specific barrier. Communicate the next step and confirm receipt and needed education or follow-up.
Scenario 10: A. An approval period and a continued-coverage requirement can have different deadlines. Track each actual requirement and allow enough time for appointments, documentation and submission. Renewal intervals and preparation timelines vary by plan and technology. A visible note alone does not replace a maintained follow-up system.
Scenario 11: B. A reliable handoff identifies who acts next, what remains, when it is due, where the record is maintained and who covers an absence. The next owner should acknowledge responsibility. Required review and signatures must be completed before submission. Match responsibilities to staff scope and organizational policy; one person may perform several roles.
This page records which answers are chosen, through the site’s analytics, to show which scenarios are missed most. It does not ask for your name. ADCES privacy policy
The Danatech Digest
Join 25,000+ professionals who get our latest diabetes technology updates
DISCLAIMERS:
This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs.
If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.
ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any
questions.
danatech is made possible thanks to a generous grant from Helmsley Charitable Trust. Additional funding provided by:
danatech, powered by ADCES, helps the whole care team choose, start, use and support diabetes technology with confidence.